Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Oct;34(4):330-2.
doi: 10.4103/0971-5851.125262.

Cisplatin induced paroxysmal supraventricular tachycardia

Waseem Raja  1 , M Hussain Mir  1 , Imtiyaz Dar  1 , Muzamil Ahmad Banday  1 , Irfan Ahmad  2
Affiliations
Case Reports

Cisplatin induced paroxysmal supraventricular tachycardia

Waseem Raja et al. Indian J Med Paediatr Oncol. 2013 Oct.

Abstract

Cisplatin or cis-diamminedichloroplatinum (CDDP) is the first member of a class of platinum-containing anti-cancer drugs that act by binding to and causing cross-linking of deoxyribonucleic acid, which ultimately triggers apoptosis. Cisplatin has a broad-spectrum antineoplastic activity against various types of human tumors. Unfortunately, the optimal usefulness of Cisplatin is limited secondary to its dose related toxicity especially nephrotoxicity. Cisplatin chemotherapy is also associated with cardiotoxic effects that may range from silent arrhythmias to heart failure and even sudden cardiac death. These effects are more pronounced when cisplatin is combined with other cardiotoxic drugs. Here, we report a case of patient of cancer lung who developed paroxysmal supraventricular tachycardia following administration of Cisplatin. A brief review of the literature follows.

Keywords: Cisplatin; lung cancer; paroxysmal supraventricular tachycardia.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1a
Figure 1a
Serial electrocardiograms
Figure 1b
Figure 1b
Serial electrocardiograms
Figure 1c
Figure 1c
Serial electrocardiograms
See this image and copyright information in PMC

References

    1. Peyrone M. On the action of ammonia on platinous. Ann Pharm Chem. 1844;51:1–29.
    1. Carpenter DP. Princeton, NJ: Princeton University Press; Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA.
    1. Ferroni P, Della-Morte D, Palmirotta R, McClendon M, Testa G, Abete P, et al. Platinum-based compounds and risk for cardiovascular toxicity in the elderly: Role of the antioxidants in chemoprevention. Rejuvenation Res. 2011;14:293–308. - PubMed
    1. Zumkley H, Bertram HP, Preusser P, Kellinghaus H, Straub C, Vetter H. Renal excretion of magnesium and trace elements during cisplatin treatment. Clin Nephrol. 1982;17:254–7. - PubMed
    1. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979;90:929–31. - PubMed

Publication types